Page last updated: 2024-09-04

cyc 202 and nu2058

cyc 202 has been researched along with nu2058 in 1 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(nu2058)
Trials
(nu2058)
Recent Studies (post-2010) (nu2058)
979739328011

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)nu2058 (IC50)
G2/mitotic-specific cyclin-B2Homo sapiens (human)7
Cyclin-dependent kinase 1Homo sapiens (human)7
G2/mitotic-specific cyclin-B1Homo sapiens (human)7
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)7
Cyclin-A2Homo sapiens (human)7
Cyclin-dependent kinase 2Homo sapiens (human)7
G2/mitotic-specific cyclin-B3Homo sapiens (human)7
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)7

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ferguson, M; Fersht, A; Finlan, L; Hupp, TR; Ibbotson, S; Luciani, MG; Rankin, EM1

Other Studies

1 other study(ies) available for cyc 202 and nu2058

ArticleYear
The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
    Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:1

    Topics: Antineoplastic Agents; Binding Sites; CDC2-CDC28 Kinases; Cell Death; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Guanine; Humans; Mutation; Peptide Fragments; Phosphorylation; Protein Binding; Purines; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2004